TPCE联合CT引导经皮微波消融序贯治疗中晚期非小细胞肺癌的临床疗效分析

TPCE Ccombined with CT Guided Percutaneous Microwave Ablation for Advanced Non-small Cell Lung Cancer

[目的]探讨经支气管肺动脉化疗栓塞(TPCE)联合CT引导经皮微波消融序贯治疗中晚期非小细胞肺癌(NSCLC)的临床疗效和生存率.[方法]回顾性分析本院收治的116例中晚期肺癌患者的临床资料,根据治疗方法的不同将其分为观察组和对照组,每组各58例.对照组患者予以TPCE治疗,观察组患者采用TPCE联合经皮微波消融(PMAT)序贯治疗.治疗后3个月行增强CT检查,比较两组患者的治疗效果.比较两组治疗前后血清血清癌胚抗原(CEA)、糖类抗原125(CA125)、血管内皮生长因子(VEGF)水平.随访3年,记录1、2、3年的生存率.[结果]观察组患者疾病控制率为84.5%(49/58),高于对照组患者的67.2%(39/58),差异有统计学意义(χ^2=4.708,P<0.05).治疗后3个月,两组血清CEA、CA125、VEGF水平均下降,且观察组明显低于对照组,差异有统计学意义(P<0.05).观察组患者术后1、2、3年的生存率明显高于对照组,差异有统计学意义(P<0.05).[结论]TPCE联合PMAT序贯治疗可明显提高NSCLC治疗效果,提高患者生存率.

[Objective]To investigate the clinical effect and survival rate of TPCE combined with CT guided percutaneous micerowave ablation in the treatment of advanced non small cell lung cancer(NSCLC).[Methods]The clinical data of 116 patients with advanced lung cancer in our hospital were analyzed retrospectively.According to different treatment methods,they were divided into observation group and control group,58 cases in each group.TPCE was given to the patients in the control group,and tpce combined with percutaneous microwave ablation(PMAT)was used in the observation group.Three months after treatment,contrast enhanced CT was performed to compare the therapeutic efect of the two groups.Serum CEA,CA125 and VEGF levels were compared before and after treatment.The survival rates of 1,2,3 years were recorded.[Results]The disease control rate of the ob-servation group was 84.5%(49/58),higher than that of the control group(67.2%)(39/58),the difference was statistically significant(χ^2=4.708,P<0.05).Three months after treatment,the serum CEA,CA125 and VEGF levels of the two groups decreased,and the difference was statistically significant(P<0.05).The 1,2,3-year survival rate in the observation group was significantly higher than that in the control group(P<0.05).[Conclusion]TPCET combined with PMAT sequential treatment can significantly improve the therapeutie ffect of NSCLC and improve the survival rate of patients.